

PROMOTION RECOMMENDATION
UNIVERSITY OF MICHIGAN MEDICAL SCHOOL
DEPARTMENT OF UROLOGY

Approved by the Regents

May 17, 2007

Mark L. Day, Ph.D., Associate Professor of Urology, with tenure, Department of Urology, Medical School, is recommended for promotion to Professor of Urology, with tenure, Department of Urology, Medical School.

Academic Degrees:

Ph.D.	1992	Washington University
B.S.	1983	Indiana University

Professional Record:

2001–Present	Associate Professor of Urology, University of Michigan
1995–2001	Assistant Professor of Surgery, University of Michigan
1992–1995	Instructor of Urologic Surgery, Washington University

Summary of Evaluation:

Teaching: Dr. Day has been an integral part of the graduate programs of Cellular and Molecular Biology and Biomedical Sciences since he began his association with the University of Michigan in 1995. He has been the Course Director of the Cancer Biology Course since 2003. He is the Director of the course in GU Oncology Research in the Department of Surgery. He has been on the dissertation committee of ten students and has been the mentor of eight postdoctoral fellows. In addition, he has been a laboratory mentor for two M.D. urology residents. There are seven graduate students working in his laboratory.

Dr. Day is widely viewed as a superior teacher as is evident by his participation in national programs and internal evaluations at the University of Michigan. He has been a visiting lecturer at Emory University, the University of Virginia, the University of Iowa, the University of Ulm, Germany, and Vanderbilt University, among others. He was an invited speaker at the Society of Basic Urology Research/American Urology Association in 2005.

His leadership in teaching is evident by his being named as Course Director in the Cancer Biology program. He is the only Ph.D. in the Urology Department to attract two residents to spend a dedicated year of research with him.

Research: Dr. Day has established himself as an international expert in prostate cancer basic science research. His primary interest is the developmental aspects of prostate cancer. The theme of research has followed the Rb pathway and, more recently, methylation abnormalities. The caliber of his current research is evident by two RO1 grants and a Department of Defense grant. He was previously principal investigator on three nationally peer-reviewed grants.

The volume of publications by Dr. Day is at the lower end of the spectrum for individuals achieving promotion to the rank of professor. However, it is noteworthy that he is published in such high quality journals as the *Journal of Biological Chemistry* and *Cancer Research*. Of note, in 2005/2006, he has had four papers published in *Cancer Research*. Although the volume of publications may be lower, the quality and caliber of the papers have been outstanding. Dr. Day has developed an international collaboration with Drs. Kuefer, Hautmann, and Gschwend from Ulm and Munich, Germany.

He is a reviewer for major peer-reviewed journals and has served on national study sections from the Department of Defense, National Science Foundation, and the National Institutes of Health. He is a member of the National Cancer Institute's Cancer Biology Training Grant Fellowship Selection Committee and the Executive Committee for the Society for Basic Urology Research.

Recent and Significant Publications:

McCabe MT, Davis JN, Day ML: Regulation of the DNA methylation and gene silencing through the pRb/E2F1 pathway. *Cancer Research* 65:3624-3632, 2005.

Davis JN, McCabe MT, Hayward SW, Day ML: The Regulation of COX-2 expression and function by E2F1 in prostate epithelium. *Cancer Research* 65:3633-3642, 2005.

Rios-Doria J, Kuefer R, Ethier SP, Day ML: Cleavage and activation of b-catenin by calpain in prostate and mammary tumor cells. *Cancer Research* 64:7237-7240, 2004.

Rios-Doria J, Day KC, Kuefer R, Rashid MG, Day ML: Calpain-mediated inactivation of E-cadherin in prostate and mammary epithelial cells. *Journal of Biological Chemistry* 278:1372-1379, 2003.

Day KC, McCabe MT, Zhao X, Wang YZ, Davis JN, Phillips J, Von Geldern M, Ried, T, KuKuruga MA, Cunha GR, Hayward SW, Day ML: Rescue of embryonic epithelium reveals that the homozygous disruption of the retinblastoma gene alters cell cycle and growth kinetics but does not influence prostatic differentiation or morphogenesis. *Journal of Biological Chemistry* 277:44475-44484, 2002.

Service: Dr. Day has a number of important roles within the Department of Urology; he is a member of the Urologic Research Advisory Committee, Executive Committee of the Michigan Prostate Research Colloquium, Prostate Cancer SPORE, and a member of the Cancer Center Research Committee. He is currently the principal investigator on the University of Michigan O'Brien Urology Center Grant and an NIH Urology Research Training Grant. He has been a guest speaker in the past for American Cancer Society events in the State of Michigan. He has given presentations at most of the Society of Basic Urologic Research meetings over the last several years.

External Review:

Reviewer A: "I consider Mark to be one of the leading basic scientists working in the field of prostate cancer research today. His biochemical and cell biological studies are among the most rigorous in the field and are also of potentially high impact with respect to possibilities for clinical translation....Mark has also demonstrated commitment to teaching and mentorship to junior scientists and clinicians. Overall, he has the research and teaching experience, the funding track record, and the national visibility required of a scientist at the professor rank at a major academic center. Within the field of urology, there are only a handful of basic scientists who in my estimation would be comparable to Mark with respect to quality of scholarship and impact on the field."

Reviewer B: "His research has both national and international impact....His credentials are well recognized as evident from the numerous study sections he has served on...He is currently the PI on two R01 grants, one DOD, an NIH Training Grant and the NIH-P50 O'Brien Urology Center. This is a very impressive record of funding and the later two grants demonstrate his leadership ability to organize large group grants successfully....Taken together, he demonstrates national service as well as a commitment to education."

Reviewer C: "His research has always been on the cutting edge. He has made significant discoveries during his scientific career....Publications of his work have consistently been of outstanding quality in journals of excellent repute. The quality of Mark's research has caught the attention of scientists at the national level....He is an outstanding scientist who has all of the necessary credentials to be promoted to Professor with tenure at any major academic institution."


Reviewer D: "I think he has been one of the leaders in the molecular characterization of prostate cancer in the field of urology....He has superb grant support and has received a number of large grants including RO1 grants, and he is well funded through the next few years. He has been on many study sections including study sections from [the] NIH and NCI. These positions testify to his prominence in the field of oncology."

Reviewer E: "He is well known for and has made substantial observations regarding the Rb/E2F pathway in prostate cancer and has published his work in substantial peer reviewed journals....He is often an invited speaker at national meetings, and I would rank him in the upper level of investigators of his peers."

Summary of Recommendation:

Dr. Mark Day is an outstanding scientist with a history of innovation and successful funding, even in today's hostile research support environment. He plays an important educational role not only in the Department of Urology but in the Cellular and Molecular Biology program. He has important administrative responsibilities as principal investigator for the UM O'Brien Urology Research Center Grant and the NIH Training Grant in Basic Research. Dr. Day's

research is evolving into a more translation focus, which will correspond even more with the emerging themes in the Department of Urology. I strongly recommend his promotion to Professor of Urology.

A handwritten signature in black ink, appearing to read "J. O. Woolliscroft", written over a horizontal line.

James O. Woolliscroft, M.D.
Interim Dean
Lyle C. Roll Professor of Medicine

May 2007